undamentalytics Newsletter
Sign in

Axsome Therapeutics, Inc. income statement

In fiscal 2025, Axsome Therapeutics, Inc. reported revenue of $638m, up 65.5% on the year before, operating income of −$167m (a -26.1% margin) and net income of −$183m, or −$3.68 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue50271386638865
Cost of revenue5————
Gross profit45————
Research and development5898187183198
Selling, general and administrative159323411571766
Operating income−180−232−281−167−151
Interest expense−10−20−22−16−7
Income before tax−187−238−287−184−157
Income tax010−11
Net income−187−239−287−183−157
Diluted EPS−$4.60−$5.27−$5.99−$3.68−$3.05
Diluted shares (average)41m45m48m50m52m
EBITDA−180−231−280−166−151

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AXSM vs SUPNAXSM vs CORTAXSM vs HRMYANIP vs AXSM

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Axsome Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Axsome Therapeutics, Inc.